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Bordetella pertussis isagram-negative coccobacillus that is theetiologic agent ofper-
tussis (whoopingcough) . Pertussis may be characterizedby episodes of paroxysmal
coughing and can be fatal, especially in children less than 1 year old. The World
Health Organization estimates that 600,000 deaths per year are due to pertussis,
most of them inunimmunized infants (1) . In the United States, widespread immu-
nization of children with an inactivated whole cell pertussis vaccine has been suc-
cessful in controllingdisease (2) . However, certain local and systemic reactions, such
as pain and swelling at the injection site and fever, have been associated with the
whole cell pertussis vaccine (3, 4) . To formulate a safe and effective acellular per-
tussis vaccine, current research efforts have been directed towards characterizing
purified antigens ofB . pertussisand analyzing their potential as protective antigens .
The 69-kD outer membrane protein (OMP)' of B . pertussis is a nonfimbrial
membrane-associated protein that induces agglutinating antibodies in mice (5). The
69-kD OMP is detectable on all virulent strains of B . pertussis (6) and an antigeni-
cally similar protein is found on the closely related Bordetella species B . parapertussis
and B . bronchiseptica (5) .
We have analyzed the ability of the69-kDOMP to protect neonatal mice against
lethal B . pertussis respiratory challenge . Aerosol infection of mice is a suitable model
for the analysis of protection in that certain parameters of the disease process in
humans, including adherence ofB . pertussis to the ciliated epithelium of the respira-
tory tract, leukocytosis, and an age-related severity ofsymptoms, are also observed
in mice (7-10) . In addition, we demonstrate thehuman immunogenicity of this protein
by examining the antibody response in children receiving a single dose ofan acel-
lular vaccine that, as we report here, contains significant amounts ofthe69-kDOMP
Materials and Methods
Mice.
￿
BALB/cAnNcR mice were obtained on day 3 post partum (pp), with mothers, from
the Animal Production Program, Division of Cancer Treatment, National Cancer Institute,
Frederick, MD .
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Rockville Pike, Bethesda, MD 20892 .
1 Abbreviations used in this paper: OMP, outer membrane protein ; pp, postpartum ; WBC, white blood
cell .
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Antigens.
￿
The 69-kD OMP was affinity purified from B. pertussis BP353 as previously de-
scribed (5). Briefly, heat extracts of B. pertussis BP353, passed through a fetuin-Sepharose
column to remove pertussis toxin, were adsorbed to a column ofagarose-linked mAb BPE3
(IgM anti-69-kD OMP), washed, and the bound antigen was eluted with 6 M urea. The
preparations of 69-kD OMP used were pure as monitored by SDS-PAGE followed by silver
staining (11). Purified 69-kD OMP is frequently observed as a doublet band by SDS-PAGE
(5). These preparations contained <0.25% endotoxin as determined by a Limulus amoebo-
cyte assay (12), and were free of contaminating pertussis toxin, as determined by the Chinese
Hamster Ovary cell agglutination assay (13).
Pertussis toxin was purchased from the Michigan Department of Public Health and was
demonstrated to be pure by SDS-PAGE. Pertussis holotoxin was inactivated with 0.15%
glutaraldehyde as previously described (14). A portion of the 69-kD OMP was also treated
with 0.15% glutaraldehyde by the same method.
Pertussis toxoid, 69-kD OMP, and tetanus toxoid (Connaught Laboratories Inc., Swift-
water, PA) were diluted in PBS containing 0.2% gelatin and adsorbed at 4°C overnight to
aluminum hydroxide gel (Superfos a/s; Vedbaek, Denmark). Mice were immunized on days
5 and 12 pp with 0.1 ml antigen administered intraperitoneally.
Samples of unadsorbed Takeda acellular pertussis vaccine, which had not been chemically
inactivated, were provided for analysis by Lederle Laboratories Division, American Cyanamid
Company, Pearl River, NY Samples ofhuman sera were provided for analysis by Dr. P Wright,
Department of Pediatrics, Vanderbilt University, Nashville, TN.
Monoclonal Antibodies.
￿
The IgGI anti-69-kD OMP mAbs BPD8 and BPE8 were purified
from ascites fluid by ammonium sulfate precipitation followed by ion-exchange chromatog-
raphy on DEAE sepharose (5). BPE3, an IgM anti-69-kD OMP mAb, was purified by am-
monium sulfate precipitation followed by gel filtraton on Sepharose 4B. The purity of each
mAb preparation was verified by SDS-PAGE. BPD8, BPE8, and BPE3 have previously been
determined to react specifically with the 69-kD OMP (5).
Protein A-Sepharose-purified 18.1.7, an IgGl anti-tetanus toxin mAb (15), was a generous
gift of Dr. Jane Halpern, Laboratory ofBacterial Toxins, FDA. The anti-FHA mAb MO8X3E
was provided by Dr. James Kenimer, Laboratory of Cellular Physiology, FDA.
In passive protection experiments, 17-d-old mice were injected intravenously with 250,ug
of purified mAb 24 h before aerosol challenge.
Aerosol Challenge.
￿
Lyophilized B . pertussis 18323 was plated on Bordet-Gengou agar con-
taining 15% defibrinated sheep blood. A 21-h culture of bacteria was harvested from slants
and resuspended in sterile saline to a concentration of _109 bacteria/mi. An aliquot of the
final suspension was diluted and plated in order to determine the viability of the challenge
inoculum.
An aerosol chamber (constructed by the Biomedical Engineering and Instrumentation
Branch, National Institutes of Health, Bethesda, MD) contained in a Biosafety Level 3 glove
box (Blickman Co., Weehawken, NJ) was used to administer the challenge inoculum to the
mice for a 30-min period ofaerosol generation as previously described (7). 1 h after termina-
tion of the aerosol challenge, at which point no viable B. pertussis can be cultured from the
surface of the mice or the chamber (7), the mice were removed and caged with filtered cage
covers. At this time, two animals were killed in order to determine the number ofviable B. per-
tussis in the lungs. All mice tested had _104 CFU in their lungs 1 h after aerosol infection.
Mice were weighed and bled periodically after infection, and any deaths were noted. Leu-
kocyte counts were determined in a model ZM Coulter counter (Coulter Electronics, Hia-
leah, FL).
Analysis ofSerum and Respiratory Ig.
￿
Mice anesthetized with 2,2,2-tribromoethanol (Aldrich
Chemical Co., Milwaukee, WI) were exsanguinated from the brachial artery. After the di-
aphragm was cut, the trachea was cut below the pharynx, and a piece of PE-50 polyethylene
tubing (Clay Adams, Parsippany, NJ) was inserted into the trachea, held in place by tight-
ening a loop of suture (6-0 silk; Ethicon, Inc., Somerville, NJ). PBS (0.3 ml) was gently in-
stilled into the lungs and withdrawn three times. The bronchoalveolar lavage fluid was cen-
trifuged to pellet leukocytes, and the supernatant was removed and frozen at -20°C until
analyzed.SHAHIN ET AL.
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Murine serum and bronchoalveolar lavage fluid were analyzed for specific antibody to the
69-kD OMP by an ELISA (15). Microtiter plates (Immunolon I; Dynatech Laboratories,
Chantilly, VA) were coated with 5 kg/ml of the 69-kD OMP in 0.1 M carbonate buffer, pH
9, and incubated overnight. The plates were washed and incubated with dilutions of mouse
serum or bronchoalveolar lavage fluid in PBS containing 0.05% Tween and 0 .2% sodium
azide for 3 h. After washing, the plates were incubated for 2 h with alkaline-phosphatase-con-
jugated goat anti-mouse total Ig, or with alkaline phosphatase-conjugated goat anti-mouse
IgM, IgG, or IgA (Southern Biotechnology, Inc., Birmingham, AL). The sensitivity and
isotype specificity of the alkaline phosphatase conjugates were established using a panel of
mAbs generously provided by Dr. John Cebra, University of Pennsylvania, Philadelphia,
PA. The plates were read 30 min after addition of Sigma 104 phosphatase substrate (Sigma
Chemical Co., St. Louis, MO), using a BioTek EL 312 reader (Biotek Instruments, Winooski,
VT). Total anti-69-kD OMP titers are expressed as the reciprocal of the endpoint dilution,
calculated by extrapolation to zero from the linear part of the titration curve. The relative
amounts of IgM, IgG, or IgA anti-69-kD OMP are reported as the OD4o5 of a 1 :100 dilu-
tion of serum or a 1 :4 dilution of bronchoalveolar lavage fluid.
Human sera were analyzed for specific antibody to the 69-kD OMP by ELISAas described
above with the following modifications. Plates coated with 2 wg/m169-kD OMP were incubated
with dilutions of human sera, washed, and were incubated overnight with alkaline phospha-
tase-conjugated goat anti-human IgG (Cappel Laboratories, Malvern, PA) before addition
of substrate. Antibody unitage was calculated by a parallel line method (16).
ElectrophoreticAnaosis.
￿
SDS-gel electrophoresis was performed by the method ofLaemmli
(17). Electrophoresis of 69-kD OMP or Takeda pertussis vaccine and transfer to nitrocellu-
lose (18) was done as previously described (5). For immunoblotting, dilutions of sera were
incubated with individual strips of nitrocellulose for 2 h at room temperature before incuba-
tion with alkaline phosphatase-conjugated goat anti-human Ig for 2 hours (Southern Biotech-
nology, Inc., Birmingham, AL), and were developed with the Protoblot substrate system
(Promega, Inc., Madison, WI).
Results
Protection Mediated by Active Immunization with the 69-kD OMP
￿
Immunization of
adult mice with our preparation of 69-kD OMP elicited polyclonal antisera that reacted
only with a single band of 69-kD when immunoblotted to tricine-urea-solubilized
antigens of B. pertussis separated by SDS-electrophoresis (data not shown).
Immunization with the 69-kD OMP protected young mice from lethal respira-
tory challenge with B . pertussis 18323. Allmice immunized on days 5 and 12 pp with
16 hg 69-kD OMP survived a respiratory challenge with B. pertussis 18323 on day
19 pp (Fig. 1); these mice exhibited a mild leukocytosis that subsequently returned
to baseline after day 21 (data not shown) and gained weight at a rate similar to unin-
fected controls (Fig. 1). Mice immunized with pertussis toxoid, as a positive control,
exhibited no leukocytosis and were protected from death (Fig. 1). In contrast, mice
immunized with tetanus toxoid and then challenged with an aerosol of B . pertussis
failed to gain weight and exhibited a pronounced leukocytosis; all ofthesemice were
dead within 19 d after challenge (Fig. 1). As the dose of 69-kD OMP per immuniza-
tion decreased from 16 to 1 ug, the proportion ofmice with severe leukocytosis (>70 x
103 WBC/I,1) increased and the percentage of survivors declined (Table I). How-
ever, -50% of the mice injected with 1 p,g 69-kDOMP survived B . pertussis respira-
tory challenge.
Since vaccine components are frequently chemically inactivated, a preparation
ofthe 69-kDOMP was treated wtih glutaraldehyde in a manner similar to that used
to inactivate pertussis toxin. This glutaraldehyde treated preparation was also pro-66
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dayafterrespiratory challenge
TABLE I
FIGURE 1.
￿
Protection against respira-
tory B. pertussis infection by immuni-
zation with the 69-kD OMP (A)
Change in peripheral WBC after B. per-
tussis aerosol challenge. Each point
represents the mean WBC/pl and SD
for an entire group, except in cases
where the (number scored/number in-
fected) is indicated on the graph due
to deaths in the group. (B) Weight gain.
The mean weight and SD for each
group is indicated. (N) indicates the
number ofmice infected: (") 81ag per-
tussis toxoid (13); (O) 8 kg tetanus
toxoid(16); (A)16ug 69-kD OMP(15);
(A) uninfected controls (10).
Survivors
50
47
87
100
92
Severe leukocytosis is defined as a count >70 x 103 WBC/Al anytime during
the 21-d period after challenge. The mean leukocyte count of uninfected mice
was 12 x 103 WBC/Al.
1 69-kD OMP treated with 0.15% glutaraldehyde.
Dose of
69-kD OMP
per injection
Dose-dependent
n
Protection by 69-kD OMP
Severe
leukocytosis`
lug %
1 16 38
4 17 47
8 15 27
16 9 0
161 12 17SHAHIN ET AL.
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tective. Of the mice immunized with 16 Ag of glutaraldehyde-fixed 69-kD OMP,
92% survived respiratory challenge with B. pertussis (Table I).
Detection ofSpecific Antibody.
￿
Serumand bronchoalveolarlavage titers of anti-69-kD
antibody were measured in mice that had been immunized days 5 and 12 pp with
8 Etg 69-kD OMP and challenged on day 19 with an aerosol of B. pertussis 18323
(Table II). A low serum IgM as well as an IgG anti-69-kD antibody response was
detected in immunized mice that were not challenged. Between 1 and 3 wk after
aerosol challenge, the reciprocal endpoint titerofanti-69-kD antibody in serum pooled
from a group of five immunized mice rose from 1,200 to 3,200; all of this antibody
was of the IgG isotype. Low levels of IgG anti-69-kD antibodies were detected in
thebronchoalveolar lavage fluid ofimmunized mice before challenge, andincreasing
amounts were detected after challenge.
Passive Protection.
￿
The mAb BPE8, a mouse IgG1 anti-69-kD OMP, passively
protected animalsagainst respiratory B. pertussisinfection when administered intra-
venously to 17-d-old mice 24 h before aerosol challenge (Fig. 2). Of the mice in-
jected with 250 Wg purified BPE8, 90% survived B. pertussis respiratory challenge,
and had peak WBC counts <70 x 103 WBC/ltl on day 16 after challenge (Fig. 2).
BPE8 was detected by ELISA in the bronchoalveolar lavage fluid of mice within
1 h after intravenous injection and at increased levels 24 h after injection (Table
III), demonstratingthat the antibody had reached the site of infection in the lungs.
In contrast to the protection observed with BPE8, 80% of the mice injected with
asecond IgG1 anti-69-kD OMP mAb, BPD8, died within 23 dafter challenge, with
all but 3 of 10 mice displaying leukocyte counts of >70 x 103 WBC/11 (Fig. 2).
BPD8 was also detected by ELISA in the bronchoalveolar lavage fluids of mice 24 h
after intravenous injection (footnote to Table III). Thus, the inability of BPD8 to
protect cannot be attributed to its failure to transude to the lungs from the circula-
tion. Passive administration of a mAb to an unrelated toxin, 18.1.7, an IgG1
anti-tetanus toxin (14), also failed to protect against B. pertussis aerosol challenge.
Detection of the 69-kD OMPin an Acellular Pertussis Vaccine.
￿
Immunoblot analysis,
using the anti-69-kD OMP mAb BPE3 (5), revealed the presence of 69-kD OMP
TABLE II
Detection ofAnti-694D OMP in Sera and Bronchoalveolar Lavage Fluid
from Immunized Mice
Mice were immunized with 8 txg69-kD OMPon day 5 and 12 pp andchallenged at 19 dof age.
" Endpoint dilution, as described in Materials and Methods.
t Absorbance at 405 nm, determined at a 1:100 dilution of serum anda 1:4 dilution of lavage
fluid. Absorbance values from unimmunized mice were 0.06 for serum IgG and IgA, 0.28
for serum IgM and 0.05 for all lavage fluids. These values were subtracted from raw data
from immunized mice.
Days
after
challenge
Total
anti-69-kD"
Serum
IgM
A4o51
IgG IgA
Total
anti-69-kD'
Lavage
IgM
A405
IgG IgA
0 200 0.44 0.28 0.04 <4 0.03 0.02 0.01
7 1,200 0 0.69 0.01 <4 0.04 0.10 0
14 1,600 0 0.65 0.01 16 0 0.44 0.02
21 3,200 0 0.96 0.02 40 0.01 0.73 0.0568 BORDETELLA PERTUSSIS PROTECTIVE ANTIGEN
4irln BA 6A 1B, IN. r "ctea Fe 08 r.> co'ro/ea
dead 0 1 8 9
Total 9 10 10 10
8
9
TABLE III
FIGURE 2 .
￿
Passive protection
against respiratory B . pertussis
infection by the mAb BPE8.
Each point represents the
number of WBC/pl of periph-
eral blood after aerosol chal-
lenge with B . pertussis 18323 .
Bars indicate the arithmetic
mean of each group . The leu-
kocyte count for mice injected
with BPE8 differs significantly
from that of mice receiving
BPD8 (p <0.05, Student's t
test) . The cumulative number
of deaths at day 23 after chal-
lenge over the total number in-
fected is also shown for each
group .
Mean absorbance and range of five animals per timepoint, determined at a
1 :100 dilution of serum and a 1:4 dilution of lavage fluid by ELISA, using
microtiter plates coated with purified 69-kDOMP . Background absorbances
(405 nm) of sera and lavage fluid from uninjected mice were 0.15 and 0.14,
respectively . Theabsorbance ofpooled serum and lavage fluid from mice 24 h
after intravenous injection with BPD8 was 0.77 and 1 .4, respectively .
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Appearance
Time after
inoculation
ofBPE8 in Bronchoalveolar Lavage Fluid
of Intravenously Injected Mice
A405'
h
Lavage
1 0.47 (0.27-0.64)
6 0.56 (0.48-0.77)
25 0.69 (0.50-0.94)
Serum
1 0.78 (0.75-0 .88)
6 0.62 (0.55-0.75)
25 0.59 (0.54-0.63)SHAHIN ET AL .
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in a preparation of a Takeda acellular pertussis vaccine (Fig . 3 A) . Densitometry
analysis of silver-stained gels reveals that the 69-kD OMP comprises as much as
5%, by weight, of the total protein in this preparation .
The fact that this vaccine contained the 69-kD OMP offered the opportunity to
examine the human serum antibody response to this protein . Immunoblot analysis
was done on paired sera from 10 children who had received whole cell pertussis vac-
cine at 2, 4, and 6 mo of age and then were boosted at 18 mo with the above prepara-
tion of acellular pertussis vaccine . These children were bled immediately before
receiving acellular pertussis vaccine, as well as 1 mo after the 18-mo booster dose .
6 of the 10 paired samples had a marked increase in reactivity with purified 69-kD
OMP in postimmunization serum taken 1 mo after boosting . Immunoblot analysis
of two of these paired sera is shown in Fig . 3 B . The IgG anti-69-kDOMP serum
antibody response, measured in four of the six paired sera by ELISA, is shown in
Table IV. All four individuals demonstrated 10-100-fold rises in IgG anti-69-kD
OMP in response to immunization with the Takeda acellular vaccine containing
69-kD OMP.
Discussion
We have demonstrated that the 69-kDOMP is a protective antigen in an animal
model ofB. pertussis respiratory infection . Neonatal miceimmunized with the 69-kD
OMP or a glutaraldehyde-treated preparation of 69-kD OMP before respiratory
challenge were protected from death and did not exhibit the severe leukocytosis and
weight loss observed in unprotected controls . Protection was dose dependent, as only
50% of the mice immunized with 44 ltg 69-kD OMP survived B . pertussis respira-
tory challenge . That antibody-mediated protection was due to immunological reac-
tivity to the 69-kDOMP and not due to a contaminant in the preparation was estab-
lished as polyclonal antisera raised to the 69-kD preparation reacted with a single
FIGURE 3 .
￿
Presence of the 69-
kDOMP in an acellular vaccine
and antibody response to this
protein after vaccination . (A) A
sample (20 lug) of unadsorbed
vaccine that had not been chem-
ically inactivated was separated
by SDS-PAGE and stained with
silver (lane 1) or transferred to
nitrocellulose and probed with
a mAb directed against FHA
(lane 2) or the anti-69-kD
OMP mAb BPE3 (lane 3). (B)
Nitrocellulose filters containing
purified 69-kD OMP were
probed with BPE3 (lane 1) or
with human sera (1 :100) col-
lected before (lanes 2 and 4) or
30 d after (lanes 3 and 5) ad-
ministration of the vaccine
shown in A . The positions of
molecular mass markers and the
69-kD OMP are shown .'J0
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TABLE IV
IgG Antibody Response to 69-kD OMP in 18-Mo-Old Children'
Receiving a Single Immunization with a T-type Acellular Pertussis Vaccine
" Children had previously received whole cell pertussis vaccine at 2, 4, and 6
months of age.
1 Units of antibody activity as measured by ELISA on microtiter plates coated
with purified 69-kD OMP. Reference serum is arbitrarily defined as contain-
ing 50 U/ml of IgG anti-69-kD OMP. Antigen-coated wells incubated with
PBS instead of serum gave values of <2 U/ml.
band of 69-kD when blotted to solubilized antigens ofB. pertussis separated by SDS
electrophoresis. Active immunization of neonatal mice with 69-kD OMP resulted
in detectable levels of IgG anti-69-kD OMP antibody in the serum at the time of
aerosol challenge. Although antibody to the 69-kD OMP was not detected in the
lungs at the time of aerosol challenge, anti-69-kD antibodies were detected 2-3 wk
after challenge. The appearance of anti-69-kD OMP in the lungs of immunized
and challenged mice could be due to transudation of antibody from the serum as
well as to local production of protective antibody. We have previously shown that
intraperitoneal immunization of neonatal mice at days 5 and 12 pp with pertussis
toxoid disseminates a primed population of antigen-specific B lymphocytes to the
respiratory mucosa (19); this memory population may be stimulated to produce pro-
tective antibody in the lung upon respiratory challenge with B. pertussis.
The mAb BPE8 passivelyprotected mice challenged with an aerosol ofB. pertussis
against leukocytosis and death, while BPD8 did not. Both BPE8 and BPD8 could
be detected in the lungs of mice 24 h afterintravenous injection, at the time of chal-
lenge. Transudation of IgG1 antibody from the systemic circulation to the lung has
previously been demonstrated by Toewset al. (20). Since both BPE8 and BPD8 are
IgG1 mAbs that recognize the 69-kD OMP (5) and both were found in the lung
at the time of challenge, the ability of BPE8 to protect suggests that this antibody
recognizes a protective epitope on the 69-kD OMPdistinct from the epitope recog-
nized by BPD8. Alternatively, the observed differential protection could be due to
the differences in the affinity of each mAb for the 69-kD OMP IgGI antibody to
the 69-kDOMP is thus sufficient to prevent leukocytosis anddeath in neonatal mice
challenged with B. pertussis, presumably by transudation from the serum to thelung,
although active immunization with the 69-kD OMP may elicit mechanisms ofpro-
tective immunity in addition to serum antibody.
The mAb BB05, which was raised to the 68-kD protein of B. bronchiseptica, and
which reacts by immunoblot with the 69-kD protein purified from B. pertussis (5),
has been shown to passively protect mice from atrophic rhinitis and death when
challenged with an aerosol ofB. bronchiseptica (21). Active immunization ofpregnant
sows with the 68-kD OMP purified from B. bronchiseptica has also been shown to
Patient no.
IgG antibody to 69-kD OMP1
Preimmunization Postimmunization
U/ml
1 24 3,000
2 9 100
3 42 6,100
4 130 4,700SHAHIN ET AL.
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prevent atrophic rhinitis inyoungoffspringchallenged intranasally with B. bronchiseptica
(22). Presumably these piglets were protected by specific antibodyinmother's milk,
as there is no transplacental transfer of Ig in ungulates (23). Thus both the 69-kD
OMP purified from B. pertussis and an immunologically related proteinisolatedfrom
B. bronchiseptica have been shown to be protective antigens.
We show here that significant amounts of the 69-kD OMP are detectable in a
T-type acellular vaccine prepared by Takeda. T-type vaccines are sucrose gradient-
purified preparations of B. pertussisextracts that have been demonstrated to contain
a mixture of antigens, including pertussis toxin, filamentous hemagglutinin, and
fimbriae (24, 25). Since purified FHA is easily degraded and commonly runs as
several bands on an acrylamide gel, includingsomenear69-kD, the presence of69-kD
OMP in a Ttype acellular pertussis vaccine has until now gone undetected. Using
mAbs specific for these antigens we have demonstrated the presence ofthe 69-kD
OMP as well as FHA in the vaccine by immunoblotting.
Inthe preliminary studiesdescribed here, anantibody response tothe69-kDOMP
wasdetected byimmunoblot analysis in 18-mo-old children boostedwith theTakeda
acellular pertussis vaccine. One to two log increases in the concentration ofserum
anti-69-kD OMP antibodieswere also detected by ELISA. Serum antibody responses
tothe 69-kDOMP havealso been detected in children within 3-9 mo aftercomplet-
ing a course ofvaccination with whole cell vaccine (26), as well as in convalescent
serum and saliva (27). In addition, De Magistris et al. have demonstrated that sev-
eral human T cell clones, derived from a volunteer convalescent from pertussis,
specifically proliferated in response to stimulation with 69-kD OMP purified from
B. pertussis (28). The 69-kD OMP antigen, therefore, elicits both B cell-mediated
and T cell-mediated immunity in humans.
The majority ofthe doses ofacellular vaccine administered inJapan are T-type,
containing inactivatedpertussistoxin, filamentous hemagglutinin, and surface pro-
teins that induce agglutinating antibodies (4). The ability of a whole cell pertussis
vaccine to elicit agglutinating antibody has previously beencorrelated with clinical
protection (29). However, it remains to be established if serum antibodies to the
69-kD OMP will provide a correlate of protective immunity for acellular pertussis
vaccines.
We havedemonstrated thatthe 69-kDOMP inducesagglutinatingantibodies (5),
elicits specific antibody detected in the serum and lungs of mice, and is protective
inamurine model ofB . pertussisinfection. A passivelyadministered anti-69-kDOMP
mAb, detected in thelungs at the time ofchallenge, was also found toprotect mice.
We further showthat the 69-kD OMP elicits an antibody response in humans, and
is present in an acellular pertussis vaccine preparation. The 69-kD OMP has re-
cently been cloned and sequenced (6) and a protocol suitable for the large scale
purification of antigen has recently been developed (30). Thus, the availability of
sufficient quantities of purified antigen will allow for the analysis of the role and
mechanism of the 69-kD OMP in eliciting protective immunity in humans.
Summary
Immunization with the 69-kD outer membrane protein (OMP) ofBordetella per-
tussis protected neonatal mice against lethal respiratory challenge with B. pertussis
18323. Active immunization elicited a serum IgG anti-69-kD OMP responseat the72
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time of challenge, with IgG anti-69-kD OMP antibodies detected in bronchoalveolar
lavage fluid after challenge. Intravenous administration ofBPE8, a monoclonal IgG1
anti-69-kD OMP, also protected young mice against B. pertussis challenge. Intrave-
nously injected BPE8 was detected in the lungs of mice at the time of aerosol chal-
lenge, suggesting that the presence of specific antibody in the lungs may mediate
protection. Thus the 69-kD OMP of B. pertussis is a protective antigen in mice that
elicits specific serum antibody that can transude to the lung.
The 69-kD OMP was detected in a preparation of a Takeda acellular vaccine by
immunoblot analysis and a serum antibody response to the 69-kD OMP was ob-
served in 18-mo-old children boosted with this preparation ofJapanese acellular vac-
cine. Our results demonstrate that the B. pertussis 69-kD OMP is a protective an-
tigen in animals, is immunogenic in humans, and is present in a preparation ofacellular
pertussis vaccine that is widely used inJapan. These findings indicate that the 69-kD
OMP should be seriously considered as a candidate for inclusion in new formula-
tions of antigenically defined acellular pertussis vaccines.
We thank Lederle Laboratories for providing Takeda acellular pertussis vaccine; Dr. Peter
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Monika Simmons, Julie Hannah, Theresa Romani, and Jeanine Gould-Kostka for expert
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